4 ms·

Or life insurers paying for ongoing GLP-1s instead of potentially the health insurer. But to your broader point, at least in the US, incentive mis-alignment on

Or life insurers paying for ongoing GLP-1s instead of potentially the health insurer. But to your broader point, at least in the US, incentive mis-alignment on all healthcare and health insurance is possibly irredeemably broken.

toomuchtodo 1y ago
Nailed my broader point. Could we go through contortions to see who is going to pay unreasonable costs for GLP-1s (health insurance, life insurance)? We could, but that's silly accounting to see who still gets to make the profit and who has to end up with the bill for empowering the human to fix their reward center. The shortcut is to provide GLP-1s to everyone who needs them at scale, as inexpensively as possible (to pull forward the improvement in health and quality of life outcomes until improved protocols arrive). The semaglutide patent is about to expire in Canada, China, India, and Brazil, for example. https://www.labiotech.eu/in-depth/novo-nordisk-semaglutide-patent-expiration-canada/ https://www.labiotech.eu/in-depth/novo-nordisk-semaglutide-p...